TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of GERD with symptoms for at least 6 months with at least 3 episodes a week and one of those at nighttime~* in generally good health~* stop any previous similar (proton pump inhibitor) therapy at least 10 days before screening~* weigh within normal weight for one's height~* able to tolerate a nasogastric tube (pH probe assembly that goes through the nose into the stomach) for 48 hours on 2 different occasions~* esophageal acid exposure of at least 10% on a 24-hour pH monitoring study performed within the 24 months prior to screening~* Helicobacter pylori (an infection) negative~* willing to take only TUMS antacid as rescue medicine during the washout period~Exclusion Criteria:~* History of a serious medical condition~* significant gastrointestinal illness other than GERD~* ulcer at any time in the past~* difficulty swallowing~* history of gastrointestinal disease (including bleeding)~* use of any medication that changes acid secretion or gastrointestinal movement in the past 14 days~* use of any drugs on a list of prohibited drugs within 1 month~* chronic use of pain relieving medications (NSAIDs or COX-2 inhibitors)~* pregnant or breast-feeding~* cancer diagnosis or treatment (except for superficial skin cancers)~* abusing drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3462817 in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of adult onset RA as defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for at least 3 months prior to screening~* Have moderately to severely active RA defined by the presence of ≥6 swollen joints (based on 66 joint count) and ≥6 tender joints (based on 68 joint count) at screening and baseline. The distal interphalangeal joint should be evaluated but not included in the total count to determine eligibility~* Have at least 1 of the following:~  * positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at screening, OR~ * previous radiographs documenting bony erosions in hands or feet consistent with RA~* Have C-reactive protein (CRP) \>1.2 times upper limit of normal (ULN) per the central laboratory at screening~* Demonstrated an inadequate response to, or loss of response or intolerance to:~  * at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) treatment OR~ * at least 1 biologic DMARD/tsDMARD treatment~Exclusion Criteria:~* Class IV RA according to ACR revised response criteria~* Have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of:~  * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or~ * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline~* Have presence of confirmed cervical dysplasia~* Have had various types of infection within 3 months of screening or develops any of these infections before the randomization visit.~* Have any of the following:~  * Human immunodeficiency virus (HIV) infection~ * Current infection with hepatitis B virus (HBV) (i.e., positive for hepatitis B surface antigen and/or polymerase chain reaction (PCR) positive for HBV DNA~ * Current infection with hepatitis C virus (HCV) (i.e., positive for HCV RNA)~ * Active tuberculosis (TB)~* Have failed more than 2 biologic DMARDs (bDMARDs) or tsDMARDs (e.g. excluded if have received 2 bDMARDs and 1 tsDMARD)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3462817 300 mg (Type: EXPERIMENTAL): Participants received Intravenous (IV) infusion of 300 mg LY3462817 solution.
- LY3462817 700 mg (Type: EXPERIMENTAL): Participants received IV infusion of 700 mg LY3462817 solution.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received IV infusion of 0.9% sodium chloride solution (Placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Trial of ADR-001 for IgA Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. IgA nephropathy diagnosed by renal biopsy.~2. Meet any of the following criteria.~   i. Urinary protein at screening is 0.5 g / gCr or more and eGFR is 60 mL / min / 1.73m\^2 or more even if corticosteroids are used for 6 months or more before screening.~   ii. Urine protein of 1.0 g / gCr or more and eGFR of 30 mL / min / 1.73 m\^2 or more and less than 60 mL / min / 1.73 m\^2 at screening even if corticosteroids are used for 6 months or more before screening.~   iii. Urine protein of 0.5 g / gCr or more and less than 1.0 g / gCr at screening and eGFR of 20 mL / min / 1.73m\^2 or more and 60 mL / min / 1.73m\^2 or urine protein of 1.0 g / gCr or more at screening And eGFR is 20 mL / min / 1.73m\^2 or more and less than 30 mL / min / 1.73m\^2.~3. Over 20 years old.~4. Able to provide informed consent.~However, in the first cohort, only 2) -i is applied in the selection criteria 2), and in the second cohort, 2) -i, ii, and iii are applied.~Exclusion Criteria:~1. Nephropathy other than IgA nephropathy, and primary and secondary nephrotic syndrome.~2. Start or increase drug therapy for IgA nephropathy with corticosteroids, immunosuppressants, renin angiotensin system (RAS ) inhibitors, antiplatelet drugs, anticoagulants (warfarin), and n-3 fatty acids (fish oil) within 3 months . Palatal tonsillectomy within 6 months.~3. Treatment with other cells.~4. Participated within 3 months or participating in other clinical trials .~5. Penal transplantation within 3 years or scheduled.~6. Diabetics not well controlled.~7. Malignant neoplasm or history of malignant neoplasm within 5 years, or judged possibility of malignant tumor.~8. Suspected of active infection.~9. Positive for hepatitis B (HB), hepatitis C virus (HCV),human Immunodeficiency virus (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.~10. History of severe hypersensitivity or anaphylactic reaction.~11. Allergic to penicillin antibiotics, aminoglycoside antibiotics or dimethyl sulfoxide (DMSO).~12. Serious complications not related to IgA nephropathy.~13. Bleeding or may bleed, shallow days after surgery or trauma to the central nervous system, history of hypersensitivity to components of heparin preparations, history of heparin-induced thrombocytopenia Previous patient.~14. During pregnancy, lactation, may be pregnant or both men and women who do not agree to give birth control under the guidance of the investigator or investigator during the study period.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADR-001 (Type: EXPERIMENTAL): Intravenous infusion of ADR-001 (Mesenchymal stem cell)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Female between 18 and 80 years of age;~* Scheduled to undergo an abdominal hysterectomy with or without bilateral salpingo-oophorectomy due to uterine leiomyomas, or dysfunctional uterine bleeding or endometrial hyperplasia;~* Anesthesiological and surgical procedures performed according to protocol;~* Moderate or severe baseline pain following hysterectomy on a Verbal Rating Scale (VRS) within 6 hours following the last possible application of morphine subcutaneous;~* Pain following hysterectomy of at least 4 on an 11-point Numeric Rating Scale (NRS) within 6 hours following the last possible application of morphine subcutaneous;~* American Society of Anesthesiologists (ASA) classification I-III.~Exclusion Criteria:~* Vaginal hysterectomy;~* Ongoing or known history of painful endometriosis;~* Known or suspected chronic pelvic pain syndrome;~* Previous abdominal or pelvic open surgery;~* History of seizure disorder or epilepsy;~* History of alcohol or drug abuse;~* Evidence of active infections that may spread to other areas of the body;~* severely impaired renal function, moderately or severely impaired hepatic function,~* Allergy or hypersensitivity to oxycodone, morphine, fentanyl hydromorphone, heparin, or any compound planned to be used during the anesthesia;~* Serious complication during surgery and up to randomization;~* Pre-operative use within 12hours prior to surgery or peri-operative use of non-steroidal anti-inflammatory drugs (NSAIDs);~* Treated regularly with opioid analgesic or non-steroidal anti-inflammatory drugs (NSAIDs) within 30 days prior to screening;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Morphine (Type: ACTIVE_COMPARATOR): None
- Tapentadol 50 mg immediate release (Type: EXPERIMENTAL): None
- Tapentadol 75 mg immediate release (Type: EXPERIMENTAL): None
- Tapentadol 100 mg immediate release (Type: EXPERIMENTAL): None
- Matched placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)~* Clinical stage III\~IVb(UICC 7th)~* Meet at least one factor below :1 primary tumor SUVmax\>10 in 18F-FDG PET/CT;2 primary tumor volume\>30cm3;3 mutiple metastatic cervical lymph node with at least one's short diameter\>4cm; 4 T4N2M0; 5 T1-4N3M0;6 EBV-DNA\>2×10E4 copy/l~* Range from 18～70 years old~* WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L~* ALT or AST \< 2.5×ULN、bilirubin \< 1.5×ULN~* OSerum creatinine \< 1.5×ULN~Exclusion Criteria:~* Central nervous system metastases~* Suitable for local treatment~* Uncontrolled seizure disorder or other serious neurologic disease~* Clinically significant cardiac or respiratory disease~* Drug or alcohol addition~* Do not have full capacity for civil acts~* Severe complication, active infection~* Concurrent immunotherapy or hormone therapy for other diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Concurrent chemoradiation + adjuvant chemotherapy (Type: EXPERIMENTAL): IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
- Concurrent chemoradiation (Type: ACTIVE_COMPARATOR): IMRT combine with cisplatin concurrent chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects with overactive bladder symptoms (subject-reported) for greater than or equal to 3 months prior to Screening/Enrollment visit.~* Reported at least an average of 1 UUI episode per 24 hours in the 3-day bladder diary prior to the Randomization/Baseline visit~* Mean urinary frequency of greater than or equal to 8 micturitions per 24 hours as verified by the 3-day bladder diary prior to randomization/Baseline visit.~Exclusion Criteria:~* Subjects with any condition that would contraindicate their usage of fesoterodine including: hypersensitivity to the active substance (fesoterodine fumarate) or to peanut or soya or any of the excipients, urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe ulcerative colitis, and toxic megacolon.~* Subjects with clinically significant hepatic or renal disease or other significant unstable diseases.~* OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.~* Subjects with previous history of acute urinary retention requiring catheterization, or severe voiding difficulties in the judgment of the investigator, prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dry eye disease or Meibomian Gland Disease as evaluated by Standard Participant Evaluation for Dryness (SPEED) score, Schirmer test, Tear film breakup time and other applicable objective measures at the Screening and Baseline Visits.~* Use of an artificial tear product, lid hygiene, omega-3 supplementation, antibiotics for the treatment of dry eye disease or Meibomian Gland Disease within one year of the Screening Visit.~Exclusion Criteria:~* Chronic or recurrent epistaxis, coagulation disorders or other conditions that may increase the risk of bleeding.~* History of nasal or sinus surgery.~* Vascularized polyp, deviated septum or severe nasal airway obstruction at the Screening visit.~* Intraocular and extraocular surgery in either eye within three months of the Screening Visit or refractive surgery within twelve months of the Screening Visit.~* Cardiac demand pacemaker, implanted defibrillator, or other active implanted metallic or active implanted electronic device in the head.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thermalon (Type: ACTIVE_COMPARATOR): Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
- TrueTear™ (Type: EXPERIMENTAL): Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients that are willing and able to provide written informed consent~* age ≥ 18 years~* HCV RNA ≥ 103 IU/mL~* HCV genotype 1 or 4~* screening ultrasound excluding hepatocellular carcinoma (HCC)~* acceptable laboratory values (hemoglobin ≥8.0 g/dL, platelet count ≥40,000/mm3; AST, ALT, and alkaline phosphatase ≤10 × ULN; creatinine clearance ≥30 mL/min)~* general good health~* ability to comply with study procedures~* HIV-infected patients must have completed at least 6 months of any approved HIV antiretroviral therapy (ART) per Rwanda National Guidelines 2013, have been taking for at least 2 weeks prior to screening ART compatible with SOF/LDV (efavirenz, rilpivirine, raltegravir, dolutegravir, emtricitabine, lamivudine, zidovudine, tenofovir), have screening HIV RNA \< 200 copies/mL, and have screening CD4 T-cell count of ≥100 cells/µL~Exclusion Criteria:~* current or history of clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage)~* active tuberculosis~* other clinically-significant illness (except HCV and/or HIV) or any other major medical disorder~* active Hepatitis B infection~* difficulty with blood collection and/or poor venous access for the purposes of phlebotomy~* any IFN-containing regimen within 8 weeks prior to screening or any prior exposure to HCV-specific direct-acting antiviral agent (other than a NS3/4A protease inhibitor and SOF), current pregnancy or breastfeeding, and active drug or alcohol use or dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Harvoni (Type: OTHER): sofosbuvir/ledipasvir once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous enrollment in Immunex protocols~* No clinically significant adverse events thought to be due to etanercept (TNFR:Fc) during previous treatment.~* Negative serum pregnancy test not more than 14 days before the first dose of study drug in females of childbearing potential.~* No more than one NSAID at a dose not greater than the maximum recommended dose and stable for at least two weeks prior to administration of etanercept (TNFR:Fc). Exclusion Criteria: - Previous receipt of TNFR:Fc (p55), antibody to TNF, anti-CD4 antibody, or diphtheria IL-2 fusion protein.~* Receipt of investigational drugs or biologics (other than TNFR:Fc \[p75\]) within 1 month prior to the first dose of etanercept (TNFR:Fc) in this study.~* Receipt of DMARDs or methotrexate (except patients from 16.0014) within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.~* Receipt of cyclophosphamide within six months prior to the first dose of (etanercept (TNFR:Fc) in this study.~* Receipt of cyclosporin within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Elderly subjects (\> 64 years) with a diagnosis of primary insomnia.~Exclusion Criteria:~* History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) axis I disorder other than primary insomnia.~* Sleep apnea, or restless legs syndrome.~* Daytime napping of more than 1 hour per day.~* Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2 years prior to the screening visit.~* Unwillingness to refrain from drugs, over-the-counter or herbal medication having an effect on sleep or behavior.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABECD (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- BCADE (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- CDBEA (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- DECAB (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- EADBC (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- DCEBA (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- EDACB (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- AEBDC (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- BACED (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
- CBDAE (Type: EXPERIMENTAL): 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete